Five of the largest US pharmaceutical companies, Merck, Eli Lilly, AbbVie, Pfizer and Bristol Myers Squibb, have told the House Select Committee on China that they do not plan to start new clinical trial sites in the Xinjiang region of China or at hospitals affiliated with the Chinese military, and all five indicated they would not initiate new clinical studies at sites linked to the People’s Liberation Army, STAT reported. The committee opened investigations into the five companies last June over concerns about intellectual property exposure, military entanglements and ethical standards at trial sites in sensitive regions of the country, and said in its letters to the companies that concern over security risks is rising.
Five drugmakers rule out new China trials at military-linked sites
Merck, Eli Lilly, AbbVie, Pfizer and Bristol Myers Squibb have told a House committee they will not start new clinical trial sites in China's Xinjiang region or at hospitals affiliated with the Chinese military.
Why it matters: The commitments narrow where the largest US drugmakers can run trials in the world's second-largest pharmaceutical market, as Congress presses them over intellectual property exposure and ethics at military-linked sites.
Data as of STAT report of November 19, 2026, read in its open portion on the publisher's site; the balance of the article is subscriber-only. STAT attributes the disclosure to the House Select Committee on China. Developing item.
Sources
- Big drugmakers will halt clinical trials at some hospitals in China - STAT - 2026-11-19